Fulcrum Therapeutics Inc (FULC): Price-to-Sales Ratio

The price/sales ratio dynamics reflect the current market valuation, where the indicator reaches 6.50. Fulcrum Therapeutics business growth relies on its partnership with Sanofi and losmapimod trials. The FulcrumSeek gene correction platform provides the company with significant pricing power. The company's prospects are based on the development of breakthrough therapies for muscle and blood pathologies.

FULC: Fulcrum Therapeutics P/S Multiple 07/04/2022 - 07/29/2025

Metric breakdowns and analytics for fulcrumtx.com (FULC)

- share price and consensus valuation forecast:

Price Performance Chart Fulcrum Therapeutics Inc|FULC - Price Target Chart

- stock exchange capitalization data:

Market Valuation Fulcrum Corp|FULC - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value of a Share Fulcrum Therapeutics|FULC - Book Capitalization|Market Capitalization to Book Value Ratio fulcrumtx.com|FULC - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples information:

FULC - Company Net Income|Expected Profit Fulcrum Therapeutics|FULC - P/E Multiple|Projected Price to Earnings Fulcrum Corp|FULC - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Fulcrum Therapeutics, Inc.|FULC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Fulcrum Therapeutics|FULC - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months fulcrumtx.com|FULC - Net earnings per share growth this year|Expected earnings per share trend next year Fulcrum Therapeutics

- issuer revenue and sales details:

FULC - Company Sales|Company Projected Revenue Volume Fulcrum Therapeutics, Inc.|FULC - P/S Multiple|Forward Price to Sales Fulcrum Corp

General company analysis:FULC Fulcrum Therapeutics, Inc.

Finished products of Fulcrum Therapeutics

Screening the P/S multiple is critical for constructing a defensive portfolio, as it compares market capitalization to annual revenue to identify business overvaluation relative to actual cash flows. In the case of Fulcrum Therapeutics (FULC), this metric reflects the market value of intellectual capital and the worth of its rare geneticists, which is clearly demonstrated by the P/S chart through the lens of investment expectations.

Competing companies

VRTX (Vertex Pharmaceuticals Incorporated) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc) - Price-to-Sales Ratio|United Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Pharmaceutical)|BBIO: P/S Multiple|BGM Group Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cogent Bio|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio kerostx.com (KROS)|Market Cap to Revenue Arcturus Therapeutics ARCT|P/S Multiple ETON (etonpharma.com)|P/S Multiple Kamada Ltd KMDA|Abeona Therapeutics - P/S Multiple|mereobiopharma.com (MREO) - Market Cap to Revenue|Protalix BioTherapeutics Inc. (PLX) - Price-to-Revenue Ratio|PLRX (Pliant Therapeutics Inc) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Applied Therapeutics, Inc.|Rein Therapeutics Inc. (RNTX) - Price-to-Revenue Coefficient|Market Cap to Revenue GELS (Gelteq Limited)|P/S Multiple Aytu Therapeutics (AYTU)|Price-to-Revenue Ratio Chemomab Therapeutics Ltd. CMMB|Market Capitalization-to-Revenue Ratio SRXH|Polyrizon Limited - P/S Multiple|AEZS (zentaris.com) - Market Cap to Revenue Ratio|CYTH (Cyclo Therapeutics, Inc.) - Market Cap to Revenue|Price to Sales Inozyme Pharma, Inc. (INZY)|RPHM (Reneo Pharmaceuticals) - P/S Multiple|COSCIENS Biopharma (CSCI) - Price-to-Revenue Coefficient